Botulinum toxin A treatment for primary hemifacial spasm: a 10-year multicenter study

Botulinum toxin A (BTX) is the currently preferred symptomatic treatment for primary hemifacial spasm (HFS), but its long-term efficacy and safety are not known. To assess the long-term effectiveness and safety of BTX in the treatment of primary HFS. Retrospective review of medical records of the 1s...

Full description

Saved in:

Bibliographic Details
Published in:	Archives of neurology (Chicago) Vol. 59; no. 3; p. 418
Main Authors:	Defazio, Giovanni, Abbruzzese, Giovanni, Girlanda, Paolo, Vacca, Laura, Currà, Antonio, De Salvia, Roberto, Marchese, Roberta, Raineri, Roberto, Roselli, Francesco, Livrea, Paolo, Berardelli, Alfredo
Format:	Journal Article
Language:	English
Published:	United States 01-03-2002
Subjects:	Adult Aged Botulinum Toxins, Type A - administration & dosage Botulinum Toxins, Type A - adverse effects Botulinum Toxins, Type A - therapeutic use Drug Administration Schedule Female Hemifacial Spasm - drug therapy Humans Male Middle Aged Neuromuscular Agents - administration & dosage Neuromuscular Agents - adverse effects Neuromuscular Agents - therapeutic use Retrospective Studies Time Factors Treatment Outcome
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Botulinum toxin A (BTX) is the currently preferred symptomatic treatment for primary hemifacial spasm (HFS), but its long-term efficacy and safety are not known. To assess the long-term effectiveness and safety of BTX in the treatment of primary HFS. Retrospective review of medical records of the 1st and 10th years of treatment. Outpatient clinics of 4 Italian university centers in the Italian Movement Disorders Study Group. A series of 65 patients with primary HFS who had received BTX injections regularly for at least 10 years. Mean duration of improvement and quality of the effect induced by the preceding treatment (measured using a patient self-evaluation scale) and occurrence and duration of adverse effects in the 1st and 10th years of treatment. Using a mean BTX dose per treatment session similar to that used by others, we obtained a 95% response rate and an overall mean duration of improvement of 12.6 weeks during year 1. The effectiveness of BTX in relieving the symptoms of primary HFS, as measured by the response rate and average duration of improvement, remained unchanged in the 1st and 10th years. Patients needed statistically similar BTX doses in the 1st and 10th years. The rate of local adverse effects (including upper lid ptosis, facial weakness, and diplopia) diminished significantly in the 10th year of treatment. Treatment with BTX effectively induces sustained relief from symptoms of HFS in the long term, with only minimal and transient adverse reactions.
ISSN:	0003-9942
DOI:	10.1001/archneur.59.3.418